๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Studies with a Chinese investigative site

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the register
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University490 Fudan University472 Second Affiliated Hospital, Zhejiang University, School of Medicine404 Peking Union Medical College Hospital282 Ruijin Hospital281
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials in this register

19052 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC
NCT05894889Stage IIIB(N2) Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
Peking University
Phase 2
70
Beijing, Shanghai
2024-01-30
Recruiting
Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study
NCT06755541Primary Biliary Cholangitis (PBC)
Xijing Hospital of Digestive Diseases
Phase 3
150
Xi'an
2024-01-30
Recruiting
A Multicenter Study Based on Multi-omics Analysis to Predict the Early Prognosis and Recurrence Risk of Acute Ischemic Stroke
NCT06584565Ischemic Stroke, Acute
Nanfang Hospital, Southern Medical University
Observational
400
Guangzhou
2024-01-30
Recruiting
Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07699185Esophageal Squamous Cell Carcinoma
Tongji Hospital
Phase 2
336
Wuhan
2024-01-29
Recruiting
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
NCT05956587Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
121
Chongqing, Fuzhou, Guangzhou, Liuzhou, Luoyang, Zhengzhou, Wuhan, Changsha
2024-01-29
Active, closed
A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer
NCT06265428HER2-positive Breast Cancer
DualityBio Inc.
Phase 3
228
Bengbu, Hefei, Beijing, Jilin City, Fuzhou, Xiamen, Guangzhou, Huizhou
2024-01-29
Recruiting
Left Roof Linear, Mitral Isthmus Linear and Left Anterior Septal Linear Ablation for Non-paroxysmal AF: PROMISED Trial.
NCT06249347Atrial Fibrillation, Atrial Fibrillation, Persistent
Second Affiliated Hospital of Wenzhou Medical University
Not applicable
166
Wenzhou
2024-01-28
Recruiting
Effect of Colchicine on Perioperative Anti-inflammatory Organ Injury in Cardiac Surgery
NCT06118034Inflammatory Response, Cardiac Disease
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 3
768
Nanjing
2024-01-28
Recruiting
Constant Current Versus Constant Voltage Subthalamic Nucleus Deep Brain Stimulation in Patients with Parkinson's Disease
NCT06742450Parkinson's Disease (PD)
Xuanwu Hospital, Beijing
Not applicable
180
Beijing
2024-01-27
Recruiting
Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)
NCT06733051Natural Killer T-cell Lymphoma
Sun Yat-sen University
Phase 2
47
Beijing, Guangzhou
2024-01-27
Recruiting
Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors
NCT06186726Carbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, Chemotherapy
Jian Chen
Phase 2
48
Shanghai
2024-01-26
Recruiting
Clinical Study on the Safety and Efficacy of QY-1-T in the Treatment of HBV-associated Advanced HCC
NCT06251115Liver Cancer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
9
Shanghai
2024-01-26
Recruiting
Driving Pressure-guided Lung Protective Ventilation
NCT06361420Hypoxemia, Ventilator Lung
Yong Lin, PhD
Not applicable
43
Fuzhou
2024-01-26
Recruiting
A Clinical Study of T3011 in Subjects With Advanced Melanoma
NCT06214156Advanced Melanoma
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2
42
Beijing, Bengbu, Changchun, Chengdu, Fuzhou, Zhengzhou, Zhongshan
2024-01-26
Recruiting
PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors
NCT06244992Locally Advanced or Metastatic Solid Tumors
Pyrotech Therapeutics, Inc.
Phase 1/2
68
Guangzhou, Beijing
2024-01-26
Recruiting
A Novel Ferumoxytol-enhanced Cardiac Magnetic Resonance for the Detection of Calcified Coronary Arteries
NCT07400406Coronary Artery Calcification
The First Affiliated Hospital with Nanjing Medical University
Observational
100
Nanjing
2024-01-26
Recruiting
Phase II Study of Adjuvant SIB Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC.
NCT06205472Hepatocellular Carcinoma, Narrow Margin, Radiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
100
Beijing
2024-01-26
Recruiting
Efficacy of Anisodamine Hydrobromide Combined With Low-molecular-weight Heparin in the Treatment of Patients With Sepsis
NCT05634057Sepsis
Chen Ying
Not applicable
782
Beijing
2024-01-25
By invitation
The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
NCT06723665Prostate Cancer
Affiliated Hospital of Jiangnan University
Not applicable
50
Wuxi
2024-01-25
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
NCT06004245Advanced Solid Tumors, Colorectal Cancer
Vividion Therapeutics, Inc.
Phase 1
280
Hangzhou, Beijing, Guangzhou
2024-01-25
Active, closed
ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma
NCT06206733Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
AskGene Pharma, Inc.
Phase 3
780
Beijing
2024-01-25
Active, closed
A RCT of Low MBO Drainage Strategies
NCT06196164Jaundice, Obstructive, Cholangiopancreatography, Endoscopic Retrograde, Endoscopic Ultrasound-Guided Drainage
Peking Union Medical College Hospital
Not applicable
40
Beijing
2024-01-25
Recruiting
A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood
NCT06240689Locally Advanced Head and Neck Squamous Cell Carcinoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
104
Hangzhou
2024-01-25
Recruiting
Perioperative Dexmedetomidine on Postoperative Delirium in Patients With Brain Tumors
NCT06164314Postoperative Delirium
Beijing Tiantan Hospital
Not applicable
366
Beijing
2024-01-25
Active, closed
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
NCT06225596Metastatic Urothelial Cancer
BicycleTx Limited
Phase 2
375
2024-01-24
Recruiting
Detection of Sepsis Occurrence by Using Blood Fluorescence
NCT06689189Sepsis, Organ Damage
Ningbo Medical Center Lihuili Hospital
Observational
800
Ningbo
2024-01-24
Recruiting
Different Dose Esketamine and Dexmedetomidine for Supplemental Analgesia and Longterm Outcomes
NCT06087510Scoliosis Correction, Postoperative Analgesia, Esketamine, Dexmedetomidine
Peking University First Hospital
Phase 4
312
Beijing
2024-01-24
Active, closed
A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies
NCT06246643Solid Malignant Tumors
Bayer
Phase 2
13
2024-01-24
Recruiting
The Safety and Efficacy Evaluation of Echocardiography-guided Percutaneous Radiofrequency Ablation for Cardiac Tumors: a Single-arm, Prospective, Single-center Clinical Study
NCT06830512Heart Neoplasms
Xijing Hospital
Not applicable
40
Xi'an
2024-01-24
Active, closed
Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)
NCT06196840Neovascular Age-Related Macular Degeneration
Innostellar Biotherapeutics Co.,Ltd
Phase 2
50
Hefei, Hangzhou, Beijing, Chengdu, Guangzhou, Shanghai, Taiyuan, Tianjin
2024-01-24
Recruiting
Clinical Trial of BT02 in Patients With Advanced Solid Tumors
NCT06404905Advanced Solid Tumor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
60
Beijing
2024-01-24
Recruiting
A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies
NCT06224855Advanced Solid Tumors, Hematological Malignancies
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1
280
Hefei, Guangzhou, Changsha, Nanchang, Hangzhou
2024-01-24
Active, closed
Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer
NCT06511726Cervical Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
29
Guangzhou
2024-01-23
Active, closed
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
NCT06143891Chronic Graft Versus Host Disease
Sanofi
Phase 3
260
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan
2024-01-23
Recruiting
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
NCT06179069SCLC
Zai Lab (Shanghai) Co., Ltd.
Phase 1
339
Hefei, Beijing, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2024-01-23
Recruiting
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC
NCT06186414Non-Muscle-Invasive Bladder Cancer (NMIBC)
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
152
Beijing, Guangzhou, Haerbin, Zhengzhou, Wuhan, Changsha, Jinan, Qingdao
2024-01-23
Recruiting
Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC)
NCT06793813Stage IVB Lung Cancer, Non-Squamous
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
44
Beijing
2024-01-23
Recruiting
Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease
NCT06356662Parkinson Disease
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 1
60
Hangzhou
2024-01-23
Recruiting
Short-term Effects of Preoperative Exercise in Moderate-to-high Perioperative Risk Lung Cancer Patients
NCT06215326Lung Cancer
Guangdong Provincial People's Hospital
Not applicable
100
Guangzhou
2024-01-23
Recruiting
An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid Tumours
NCT06697665Solid Cancer
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase EARLY_PHASE1
10
China
2024-01-23
Recruiting
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
NCT06137144Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)
AstraZeneca
Phase 1/2
161
Beijing, Guangzhou, Shanghai
2024-01-23
Active, closed
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
838
Beijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hohhot
2024-01-22
Recruiting
Application of Augmented Reality Neuronavigation in Transnasal Endoscopic Skull Base Surgery
NCT06282224Pituitary Neoplasms
The First Affiliated Hospital of Xiamen University
Not applicable
10
Xiamen
2024-01-22
Not yet open
Exploring the Mechanism of Severe Acute Pancreatitis Based on Metagenomics, Metabolomics and Proteomics
NCT06230432Acute Pancreatitis
The First Affiliated Hospital of Nanchang University
Observational
176
Nanchang
2024-01-21
Recruiting
A Real-world Study of Staging and Grading of Clinical Immune Status in Chronic Hepatitis B
NCT06525909Hepatitis B, Chronic
Tongji Hospital
Observational
250
Wuhan, Beijing, Changchun, Chongqing, Nanjing
2024-01-20
Recruiting
A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer
NCT06151262Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
30
Nanjing
2024-01-20
Recruiting
Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
NCT06203249Microbiome, Immune Function, Anti-MDA5 Antibody Positive Dermatomyositis
Chinese PLA General Hospital
Observational
50
Beijing
2024-01-20
Recruiting
Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement
NCT06111612Acute Myeloid Leukemia, Myelodysplastic Neoplasm, Chronic Myelomonocytic Leukemia, Myeloid Sarcoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Observational
50
Shanghai
2024-01-20
Recruiting
A Single-Arm Clinical Trial of Percutaneous Splenic Ablation Combined With Splenic Artery Occlusion for Secondary Hypersplenism.
NCT06292715Secondary Hypersplenism
Tianjin Medical University Cancer Institute and Hospital
Not applicable
35
Tianjin
2024-01-20
Recruiting
Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer
NCT06276868Breast Cancer, HER2-positive Breast Cancer
Henan Cancer Hospital
Phase 2
71
Henan
2024-01-20
Recruiting
Prospective Registry of Endovascular Thrombectomy for eXtra-Large Ischemic Stroke
NCT06210633Acute Ischemic Stroke (AIS), Acute Ischemic Stroke From Large Vessel Occlusion
Zhongming Qiu
Observational
1,000
Xiangtan
2024-01-20
Recruiting
The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
NCT06214195Cardiotoxicity Induced by Drug Therapy for Breast Cancer
Zhejiang Cancer Hospital
Phase 3
276
Hangzhou
2024-01-20
Recruiting
Transcutaneous Electrical Acustimulation in the Treatment of Mild to Moderate Ulcerative Colitis
NCT06231264Ulcerative Colitis
Xijing Hospital
Not applicable
96
Xi'an
2024-01-19
Active, closed
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
NCT06260163Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 3
112
Beijing, Changzhou, Hangzhou, Shanghai, Shenyang, Zhengzhou
2024-01-19
Recruiting
Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension
NCT06055452Pre-Heart Failure, Hypertension
China National Center for Cardiovascular Diseases
Phase 4
120
Beijing, Shenzhen
2024-01-19
Recruiting
A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors
NCT06031584Her2-positive/Low-expression Urinary and Digestive Tract Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
42
Beijing
2024-01-19
Active, closed
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
NCT06163326Vitiligo
Pfizer
Phase 3
394
Guangzhou, Wuhan, Shenyang, Shanghai, Kunming
2024-01-19
Recruiting
Neoadjuvant Therapy of HAIC๏ผˆGEMOX๏ผ‰ Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
NCT06208462Intrahepatic Cholangiocarcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2
33
Nanjing, Chengdu, Ningbo
2024-01-19
Recruiting
MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06345365Acute Myeloid Leukaemia
Zhongnan Hospital
Phase 3
154
Zhengzhou, Huanggang, Jingzhou, Shiyan, Wuhan, Xianning, Xiaogan, Yichang
2024-01-18
Active, closed
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT06018337Metastatic Breast Cancer
DualityBio Inc.
Phase 3
541
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Huizhou
2024-01-18
Recruiting
A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
NCT06130553Advanced Solid Tumors That Are MTAP Deficient
AstraZeneca
Phase 1/2
334
Beijing, Chengdu, Shanghai, Wuhan
2024-01-18
Active, closed
Study to Evaluate Immunogenicity and Safety of TVAX-008 Injection in Non/Treated Chronic Hepatitis B Patients With HBsAgโ‰ค20IU/ml or HBsAg Negative Without Serological Conversion
NCT07204236Chronic Hepatitis B
Grand Theravac Life Sciences (Nanjing) Co., Ltd.
Phase EARLY_PHASE1
20
Jinan
2024-01-18
Recruiting
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma
NCT06151743Locally Advanced Hypopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University
Phase 2
32
Shanghai
2024-01-18
Recruiting
HS-IT101 Injection in the Treatment of Advanced Solid Tumors
NCT06342336Solid Tumor
Qingdao Sino-Cell Biomedicine Co., Ltd.
Phase 1
44
Beijing
2024-01-18
Active, closed
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
NCT06144944Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma, Early-stage Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
160
Guangzhou
2024-01-17
Active, closed
A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)
NCT05721950Non-small Cell Lung Cancer (NSCLC)
Takeda
Observational
154
Shanghai
2024-01-17
Recruiting
The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease
NCT06167681Parkinson Disease
iRegene Therapeutics Co., Ltd.
Phase 1/2
40
Beijing, Wuhan
2024-01-17
Recruiting
Safety and Efficacy Study of NGGT003 in Hemophilia A Patients
NCT06238908Hemophilia A
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1
6
Tianjin
2024-01-17
Recruiting
Fenofibrate in Primary Biliary Cholangitis: a Real World Study
NCT06755151Primary Biliary Cholangitis (PBC)
Xijing Hospital of Digestive Diseases
Phase 3
300
Xi'an
2024-01-17
Recruiting
Efficacy and Safety of Upatinib in the Treatment of Active Anal Fistulas in Crohn's Disease
NCT06902987Crohn's Diseases, Active Anal Fistula, Upadacitinib
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 1
27
Guangzhou
2024-01-17
Recruiting
GVMยฑR in Patients With Relapsed or Refractory Aggressive NHL.
NCT06244368Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
115
Tianjin
2024-01-17
Recruiting
Organ Preservation First Strategy and Intentional Watch and Wait for MRI Defined Low-risk Rectal Cancer
NCT06209099Rectal Cancer
Peking University Cancer Hospital & Institute
Not applicable
96
Beijing
2024-01-17
Recruiting
Efficacy and Safety of Mirabegron in Intracerebral Hemorrhage
NCT05369351Intracerebral Haemorrhage
Tianjin Medical University General Hospital
Phase 2
25
Tianjin
2024-01-17
Recruiting
Metabolomic Profile of Vitreoretinal Diseases: an NMR-Based Approach Using Vitreous.
NCT06429969Vitreoretinal Disease
Renmin Hospital of Wuhan University
Observational
450
Wuhan
2024-01-17
Recruiting
A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors
NCT06101082Solid Tumor
China Medical University, China
Phase 1
9
Shenyang
2024-01-16
Active, closed
Mechanism of Nitric Oxide on Ventilator-induced Diaphragm Dysfunction with Extracorporeal Membrane Lung Assistance
NCT06660784Tracheal Intubation, Extracorporeal Membrane Oxygenation, Nitric Oxide, Ventilator-induced Diaphragmatic Dysfunction
Zhongnan Hospital
Observational
80
Wuhan
2024-01-16
Recruiting
Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer
NCT06200168Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting
Jiuda Zhao
Phase 3
370
Xining
2024-01-16
Recruiting
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
NCT06211790Kidney Cancer, Renal Cell Carcinoma, Renal Clear Cell Carcinoma
Fudan University
Phase 2
66
Shanghai
2024-01-16
Active, closed
A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia
NCT06199089Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
45
Tianjin
2024-01-16
Recruiting
WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases
NCT06243003SCLC,Extensive Stage, Brain Metastases
Fudan University
Phase 1/2
56
Shanghai
2024-01-15
Recruiting
Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer
NCT06268652Breast Cancer, Refractory Breast Carcinoma
Sun Yat-sen University
Phase 3
302
Guangzhou
2024-01-15
Recruiting
Effectiveness of OLE Airway Clearance Therapy in ICU Patients With Pulmonary Infections
NCT07395297Pneumonia
Chinese PLA General Hospital
Not applicable
62
Beijing
2024-01-15
Recruiting
Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM
NCT06208371Colorectal Neoplasms Malignant
Sun Yat-sen University
Phase 3
117
Guangzhou
2024-01-15
Recruiting
Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
NCT06671548Heavy Menstrual Bleeding, Uterine Fibroids
Qilu Pharmaceutical Co., Ltd.
Phase 3
120
Beijing
2024-01-15
Recruiting
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
NCT06210776HER2-positive Breast Cancer, HER2-low Breast Cancer, Breast Cancer, Advanced Cancer
Daiichi Sankyo
Observational
800
Beijing, Chengdu, Dalian, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou
2024-01-15
Active, closed
A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome Patients
NCT06099236Atypical Hemolytic Uremic Syndrome(aHUS)
AstraZeneca
Observational
367
Beijing, Chongqing, Anhui, Fujian, Guangdong, Guangxi, Guizhou, Hainan
2024-01-15
Recruiting
Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib
NCT06478927Hepatocellular Carcinoma
Henan Cancer Hospital
Not applicable
22
Zhengzhou
2024-01-15
Recruiting
Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer๏ผšA Prospective, Single-Arm, Phase II Study
NCT07085182NSCLC, Tislelizumab, Chemotherapy, Hypofractionated Radiotherapy
Zibo Municipal Hospital
Phase 2
20
Zibo
2024-01-13
Recruiting
PRevention of OsTEoporotiC FracTure 2 Pilot Study
NCT06134908Fragility Fracture
Third Affiliated Hospital, Sun Yat-Sen University
Not applicable
50
Changsha, Dongguan, Guangzhou, Hangzhou, Hefei, Shenzhen
2024-01-13
Recruiting
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
NCT06141369Adrenal Cortical Carcinoma, Medullary Thyroid Cancer, Thymic Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Tumor
Shanghai Jiao Tong University School of Medicine
Not applicable
21
Shanghai
2024-01-13
Recruiting
A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.
NCT06267183Idiopathic Pulmonary Fibrosis
Shanghai Synvida Biotechnology Co.,Ltd.
Phase EARLY_PHASE1
53
Shanghai
2024-01-12
Recruiting
Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
NCT06197581Breast Cancer, Familial Male, Radiotherapy; Complications, Chemotherapeutic Toxicity, Immune Checkpoint Inhibitor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
148
Beijing
2024-01-12
Recruiting
A Clinical Study of CD19 Universal CAR-ฮณฮดT Cells in Active Systemic Lupus Erythematosus
NCT06106893Systemic Lupus Erythematosus
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2
15
Wuhan
2024-01-12
Recruiting
Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma
NCT06907602Locally Advanced Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital
Phase 2/3
120
Beijing
2024-01-12
Recruiting
Safety and Efficacy of XJ-Procedure in Patients With Acute Type A Aortic Dissection Surgery
NCT06199401Type A Aortic Dissection, Complication of Surgical Procedure, Aortic Diseases
First Affiliated Hospital Xi'an Jiaotong University
Not applicable
680
Xi'an
2024-01-11
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
Alexion Pharmaceuticals, Inc.
Phase 3
1,181
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou
2024-01-11
Recruiting
Multi-omics Study for Early Detection of Colorectal Cancer (MOED-CRC)
NCT06220617Colorectal Cancer, Adenomatous Polyps, Adenoma, Advanced Adenoma
Zhejiang University
Observational
3,600
Hangzhou, Guangzhou, Kunming, Nanjing, Xi'an, Zhengzhou
2024-01-11
Recruiting
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer
NCT06149130Breast Cancer
Tongji Hospital
Phase 2
82
Wuhan
2024-01-11
Recruiting
Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma
NCT06321939Nasopharyngeal Carcinoma, Herpesvirus 4, Human
Hunan Cancer Hospital
Observational
50
Changsha
2024-01-11
Recruiting
A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
NCT06219356Non-Hodgkin Lymphoma
Hangzhou GluBio Pharmaceutical Co., Ltd.
Phase 1
110
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Shenyang
2024-01-11
Rows per page Showing 13701–13800 of 19052
Previous 136 137 138 139 140 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china?page=138

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

How many clinical trials are recruiting in China?

11,786 of the 19,052 studies in this register are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3,920 have not yet opened recruitment, 2,668 are active but closed to new participants, and 678 are enrolling by invitation only. Eligibility for any study is decided by its study team.

→

Browse trials by condition

Breast Cancer (416) Advanced Solid Tumors (183) Gastric Cancer (183) Colorectal Cancer (179) Hepatocellular Carcinoma (161) Advanced Solid Tumor (159) Solid Tumor (145) Non-Small Cell Lung Cancer (144) Acute Ischemic Stroke (138) Lung Cancer (134) Pancreatic Cancer (132) Non-small Cell Lung Cancer (131) Multiple Myeloma (126) Coronary Artery Disease (111) Prostate Cancer (111)
→

Browse trials by site location

Beijing (5484) Shanghai (3827) Guangzhou (3318) Hangzhou (1812) Wuhan (1343) Chengdu (1291) Nanjing (1193) Changsha (1154) Chongqing (1056) Fuzhou (1018) Tianjin (940) Zhengzhou (921) Hefei (875) Jinan (785) Changchun (641)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.